Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function

Classic psychedelics are compounds that primarily act as agonists at the serotonin 2A receptor (5-HT2A R) and include substances such as LSD, mescaline, psilocybin, and naturally occurring DMT in ayahuasca. Earlier preclinical and human work implicates 5-HT2A R as central to the characteristic subjective and behavioural effects of these drugs, although other receptor actions (e.g. 5-HT2C, 5-HT1A, dopaminergic effects at high LSD doses, and TAAR1 activation) and downstream gene expression changes are also reported. Historically, these compounds were used sacramentally in a range of indigenous contexts and attracted major scientific interest in the 1950s–1960s for both basic neuroscience and psychiatry, with early clinical signals for cancer-related psychological distress and addiction; research largely halted in the early 1970s and re-emerged from the 1990s onward. Johnson and colleagues set out to provide an integrative review across four domains: epidemiology of classic psychedelic use, contemporary therapeutic clinical research, the construct and measurement of mystical-type experiences occasioned by psychedelics, and neuroimaging/brain network findings that might explain acute and persisting effects. The review aims to synthesise modern findings on safety, population-level associations, experimental and pilot therapeutic trials, the role of mystical-type experiences as predictors or mediators of benefit, and systems-level neural mechanisms that could underlie both altered conscious states and therapeutic outcomes.

Pharmacology and safety: The review summarises mechanistic evidence that 5-HT2A receptor agonism is necessary for many classic psychedelic effects, supported by animal discrimination studies, 5-HT2A antagonism studies in humans, and genetic knockout models. Other receptor contributions (5-HT2C, 5-HT1A, dopaminergic activity at high LSD doses, TAAR1 activation) and upregulation of immediate early genes with synaptic implications are described. Acute risks described include transient anxious or dysphoric reactions (“bad trips”), modest cardiovascular stimulation (increased blood pressure and heart rate), dose-related headaches, nausea and occasional vomiting. The authors note that prolonged psychiatric reactions appear largely limited to individuals with vulnerability to psychosis, citing historical rates from 1960s–1970s studies that ranged from 0.08% to 4.6% for psychoses after LSD exposure, with higher rates in psychiatric patients. Screening and supervised settings are emphasised as risk-mitigation strategies. Epidemiology and population-level associations: Large national surveys (Monitoring the Future, NSDUH) and other sources (DEA seizure data, Global Drug Survey) are summarised to characterise prevalence trends and harms. The Global Drug Survey (n=22,289) reported 6.2% of respondents practising microdosing, but the authors caution that this self-selected sample likely overestimates general-population use. Analyses of NSDUH data and other observational studies are reported to show either null or modestly protective associations between lifetime classic psychedelic use and mental health outcomes: several investigations found that lifetime psychedelic or psilocybin use was associated with a decreased likelihood of psychological distress, suicidality, and certain substance-use outcomes, including reduced risk of opioid abuse. Additional observational findings linked naturalistic hallucinogen use to reduced criminal recidivism and lower rates of some violent offending in specific samples. The authors repeatedly caution that these are population-level associations, not proof of causation, and reiterate the risks of unsupervised use. Therapeutic clinical research — cancer-related distress: Contemporary clinical trials using a ‘‘psychedelic’’ psychotherapeutic model (preparation, supported high-dose sessions with music and eyeshades, and integration) have produced substantial signals. A 2011 pilot (n=12) compared a moderate oral psilocybin dose (0.2 mg/kg) with niacin and reported trends and subsequent reductions in depression and anxiety scores up to 6 months, with no clinically significant psilocybin-attributable adverse events. Two larger, more recent studies used within-subject designs in patients with life-threatening cancer and anxiety/depression related to illness: one randomised/counterbalanced study in 51 patients compared a high psilocybin dose (~0.31–0.43 mg/kg) to a very low dose (~0.01–0.04 mg/kg) and found significant improvements on multiple outcomes at 5 weeks, with many effects enduring; another study using a high dose versus niacin comparators reported substantial reductions in anxiety and depression with an approximately 60% remission rate on key measures at about 6 months. In these trials, measures of mystical-type experience (MEQ scores) correlated with and statistically mediated therapeutic outcomes. Therapeutic clinical research — depression: Open-label pilot work in treatment-resistant major depressive disorder included a 12-patient study with two psilocybin sessions (10 mg then 25 mg) reporting clinically meaningful reductions. Ayahuasca trials (small inpatient samples of 6 and 17 patients) reported rapid and significant reductions on clinician-rated depression scales at 1, 7 and 21 days post-dose, with SPECT showing increased perfusion in mood-related regions (left nucleus accumbens, right insula, left subgenual area). A randomised trial of ayahuasca versus placebo (n=29 receiving intervention; n=14 ayahuasca) is noted but the extracted text reports mixed or trend-level findings in that study. The authors caution that phase 3 evidence and public funding for large mechanistic trials remain limited. Therapeutic clinical research — addiction: Older randomised LSD trials for alcohol dependence were re-analysed in a 2012 meta-analysis that found robust support for LSD improving outcomes at early follow-up. Contemporary open-label pilots include a smoking cessation study (n=15) combining cognitive behavioural therapy with multiple psilocybin sessions (~0.29–0.43 mg/kg) that reported 80% biologically confirmed abstinence at 6 months and 60% at 2.5 years; mystical-experience strength predicted successful cessation. An alcohol-dependence open-label pilot (n=10) reported large reductions in percentage drinking days and heavy drinking days after psilocybin sessions, sustained at follow-up (drinking days from ~32.5% pre-treatment to ~12.5% in the 4 weeks after session and ~17.5% at final follow-up; heavy drinking days from ~26% to ~8% then ~13%). No serious drug-attributable adverse events were reported in these pilots. The authors emphasise that these studies lack control groups and that larger randomised trials are needed. Mystical-type experience: The review details the construct of mystical experience (unity, sacredness, noetic quality, positive mood, transcendence of time/space, ineffability) and its operationalisation (e.g. MEQ30, MEQ43). Experimental studies in healthy volunteers show that psilocybin reliably induces mystical-type experiences in a dose-dependent manner: higher doses (20–30 mg/70 kg) produced ‘‘complete’’ mystical experiences in a majority of participants (around 61–67% on session day, rising to ~78% at 14-month follow-up in pooled data). Double-blind crossover work comparing psilocybin to active comparators (methylphenidate, dextromethorphan) found substantially greater mystical scores after psilocybin. Clinical therapeutic trials reported that mystical-experience scores correlated with and mediated therapeutic benefit in cancer-related distress, smoking cessation, and alcohol-dependence pilots. Systems-level neuroscience: Neuroimaging and electrophysiological studies indicate that classic psychedelics reduce the modularity and typical integration of large-scale brain networks, particularly impacting default mode network (DMN) regions such as posterior cingulate cortex (PCC) and medial prefrontal cortex (MPFC). Acute effects include decreased within-network connectivity, reconfiguration into more local networks, an increased number of distinct brain activity patterns, and increases in measures described as brain entropy. EEG/MEG work shows broadband reductions in oscillatory power, notably alpha-band decreases in PCC linked to reported ‘‘ego dissolution’’. Molecular imaging yielded findings that can appear discrepant (global decreases in absolute blood flow but relative frontal sparing or hyperfrontality); recent work reconciles this by distinguishing global from relative cerebral blood flow changes. MRS data show psilocybin-associated increases in glutamate in anterior cingulate cortex alongside decreased BOLD, suggesting a potential molecular pathway connected to antidepressant mechanisms. The authors note that enduring neuroplastic or lasting network changes have not yet been conclusively demonstrated and that mechanistic links between acute network reconfiguration, mystical experiences, and enduring clinical benefit remain an active area for research.

Johnson and colleagues interpret the body of contemporary evidence as indicating that classic psychedelics, administered within a structured psychotherapeutic framework, produce robust acute subjective effects and promising therapeutic signals across several indications, most notably cancer-related psychological distress and preliminary signals for depression and addiction. They highlight that mystical-type experiences are reliably occasioned by higher doses of psilocybin and LSD in supportive settings, and that these experiences statistically correlate with and appear to mediate many of the enduring positive psychological outcomes observed in both healthy volunteers and patient populations. The review situates these findings within earlier historical research, arguing that modern trials both replicate and extend promising signals from the 1950s–1970s era while benefitting from improved screening, controlled designs, and standardised outcome measurement. At the same time, the authors emphasise important limitations: many therapeutic studies remain small, some are open-label, and there is a need for larger randomised Phase II/Phase III trials and mechanistic studies to confirm efficacy, safety, and neural substrates. They also emphasise persistent safety concerns, including the potential for acute challenging experiences, cardiovascular effects, and the risk of precipitating prolonged psychosis in vulnerable individuals, and therefore stress screening and supervised clinical protocols. In terms of implications, the authors note that if ongoing larger trials confirm safety and efficacy—for example in cancer-related distress or treatment-resistant depression—regulatory approval and carefully controlled clinical deployment could follow. They argue that approved therapeutic use of one classic psychedelic could pave the way for investigation and development of other members of this pharmacological class, given the large number of structurally related compounds. Finally, the authors call attention to the need for substantial funding to support large-scale efficacy and mechanistic trials and observe that public funding to date has been limited; they present contemporary positive findings as a potential impetus for broader investment and further research. No separate formal conclusion section is presented in the extracted text.